Testing ropeginterferon for high-risk JAK2 mutation carriers
Part of Blood & lymphatic clinical trials.
This trial tests whether the drug ropeginterferon can help people with a JAK2 gene mutation who have additional risk factors but do not yet have a blood cancer. The goal is to see if treatment can prevent blood clots, high blood counts, or other complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years or older
- Have a JAK2 V617F mutation in the blood, without a diagnosis of a blood cancer (like MPN)
- Must have at least one high-risk feature, such as a recent blood clot, high blood cell counts, or a high level of the JAK2 mutation
- Must agree to have a bone marrow biopsy to rule out a blood cancer
- Must have adequate kidney and liver function, and acceptable blood cell counts
- Must not be pregnant or nursing, and must use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called ropeginterferon alfa-2b for people with certain blood cancers that have features of both myelodysplastic syndromes and myeloproliferative neoplasms. The drug may help control blood counts and reduce symptoms.
This study tests a new oral drug (ZE74-0282) for people with blood cancers that have a specific genetic change called JAK2 V617F. The goal is to see if the drug is safe and helps control the cancer.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
Hear when a new JAK2 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.